MedTrace Logo

A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Belgium

NCT06677892 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2025-09-09

No results posted yet for this study

Summary

Cytomegalovirus (CMV) is a common virus that infects many people. It can cause serious illness in people with weak immune systems especially in those undergoing transplants. Maribavir is a medicine approved for treating CMV infection in adults after transplant.

The main aim of this study is to check the use of maribavir and learn how safe and effective in treating adults with CMV infection after transplant in Belgium in line with the Belgian reimbursement criteria.

During the study, a participant's data will be collected for 2 years. The study does not have fixed visits to the hospital, but it is recommended collect data from routine visits and contacts.

Conditions

  • Cytomegalovirus (CMV)

Interventions

OTHER

No Intervention

This is non-interventional study.

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-24
Primary Completion
2026-08-01
Completion
2026-09-01

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06677892 on ClinicalTrials.gov